ROS 1 IHC Marker
- Sample Type
- Tissue (Biopsy)
- Fasting
- No
- Unit
- Score
Function
The ROS1 Immunohistochemistry (IHC) marker is a specialized laboratory test performed on tumor tissue to detect the overexpression of the ROS1 protein. ROS1 is a receptor tyrosine kinase; in certain cancers, the ROS1 gene undergoes a rearrangement (fusion) with other genes, leading to constitutive activation of the protein. This activation drives uncontrolled cell growth and survival. The IHC test uses specific antibodies that bind to the ROS1 protein, producing a color change visible under a microscope.
Why it is Ordered
This test is a critical component of 'Precision Medicine' for patients diagnosed with Non-Small Cell Lung Cancer (NSCLC), specifically those with adenocarcinoma histology. Identifying a ROS1 rearrangement is transformative for treatment, as these patients typically do not respond well to traditional chemotherapy but show dramatic, durable responses to targeted therapies known as Tyrosine Kinase Inhibitors (TKIs), such as Crizotinib or Entrectinib.
Associated Conditions
- Non-Small Cell Lung Cancer (NSCLC): Occurs in approximately 1-2% of all NSCLC cases, often in younger patients or 'never-smokers'.
- Glioblastoma: ROS1 fusions have been occasionally identified in brain tumors.
- Cholangiocarcinoma: Rare instances of ROS1 fusions found in bile duct cancers.
Why Context Matters
IHC for ROS1 is highly sensitive but can occasionally produce false positives (low specificity) due to background staining or the presence of the normal ROS1 protein in certain tissues. Because a positive result commits a patient to expensive and specific targeted therapy, many clinical guidelines recommend confirming a positive IHC result with a more definitive method like Fluorescence In Situ Hybridization (FISH) or Next-Generation Sequencing (NGS) to verify the actual gene fusion.
Lab ranges are statistical averages, not biological laws. "Normal" for a 20-year-old male isn't normal for a 60-year-old female.
Clinical References
Source-of-truth databases and clinical guidelines for ROS 1 IHC Marker:
Official Sources
Research & Guidelines
- PubMed: ROS 1 IHC Marker Clinical GuidelinesNCBI / PubMed
Related Indicators
Medically Reviewed by Dr. Binoy Babu, MBBS
Board Certified Doctor • 10+ Years Clinical Experience
Dr. Babu is a practicing physician dedicated to empowering patients with clear, actionable medical information. He founded 2opi to bridge the gap between complex lab reports and patient understanding, ensuring everyone has access to a reliable second opinion.
Get Notified When Dr. Babu Is Available